Ayrton Saunders Announces Landmark UK MHRA Approval of Next Generation Nicotine Inhaler System for Rapid, Safe Relief of Nicotine Craving to Aid Smoking Cessation
25 juin 2024 03h00 HE
|
OBG Pharma
Becomes the world's first and only clinically approved nicotine inhaler enabling rapid absorption via the lungs to help smokers replace, cut down, and ultimately quit smokingAs a General Sales List...
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
12 mars 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval
13 sept. 2023 03h00 HE
|
Rentschler Biopharma SE
UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapyHighly experienced team ready to support ATMP innovators at all stagesOffering comprehensive range of...
MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease
05 avr. 2023 08h35 HE
|
Advantage Therapeutics Inc.
MIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
28 juin 2022 16h01 HE
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
07 avr. 2022 11h00 HE
|
NeuroSigma, Inc.
Double-blind randomized controlled trial of eTNS for pediatric ADHD will enroll up to 150 participants at two sites in London and Southampton NeuroSigma’s Monarch eTNS System and electric patches to...
MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients
09 mars 2022 10h08 HE
|
IN3BIO
LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- IN3BIO Research Limited, a leader in developing cancer treatments that, based upon clinical data, show significant promise and appear to be more tolerable...
Pfizer und BioNTech erhalten weltweit erste Zulassung für COVID-19-Impfstoff
02 déc. 2020 02h05 HE
|
BioNTech SE
Die britische Regulierungsbehörde MHRA genehmigt die Lieferung von COVID-19-Impfstoff zur Notfallversorgung (gemäß Verordnung 174); erste Lieferungen werden innerhalb weniger Tage im Vereinigten...
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
02 déc. 2020 02h05 HE
|
BioNTech SE
U.K. regulator, MHRA, authorizes supply of COVID-19 mRNA vaccine for emergency supply under Regulation 174; Companies are ready to deliver the first doses to the U.K. immediatelyFirst authorization...
Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001
06 juil. 2020 09h25 HE
|
CELIXIR Plc
Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001 First patient successfully dosed in cardiomyopathy study Stratford-upon-Avon, UK: July, 6 2019...